Daiichi Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Toshiharu Yoshino

Noriyasu Haginoya

Tsutomu Nagata

Masatoshi Nagamochi

Hideyuki Kanno

Kenji Yoshikawa

Satoshi Komoriya

Makoto Ono

Syozo Kobayashi

Akiyoshi Mochizuki

Toshiharu Ohta

Hiroyuki Naito

Kouichi Uoto

Yumi Nakamoto

Masanori Suzuki

Masayuki Ito

Takayasu Nagahara

Haruhiko Horino

The invention relates a compound represented by the formula (1):Q-Q-C(&#x2550;O)&#x2014;N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rrepresent H or the like; Qrepresents an aromatic ring, heterocyclic ring or the like; Qrepresents a single bond, aromatic ring, heterocyclic ring or the like; Qrepresents a group or the like, Qrepresents an aromatic ring, heterocyclic ring or the like; and Trepresents &#x2014;CO&#x2014; or &#x2014;SO&#x2014;, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Ethylenediamine derivatives

A compound represented by formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)[wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qrepresents the following group: (wherein Qis an alkylene group having 1 to 8 carbon atoms, or the like); and Tand Tare carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q&#x2003;&#x2003;(1)wherein Rand Rare hydrogen atoms or the like; Qis a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Qis a single bond or the like; Qis a group in which Qis an alkylene group having 1 to 8 carbon atoms, or the like; and Tand Tare carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

The invention relates a compound represented by the formula (1):Q-Q-C(&#x2550;O)&#x2014;N(R)-Q-N(R)-T-Q&#x2003;&#x2003;()wherein Rand Rrepresent H or the like; Qrepresents an aromatic ring, heterocyclic ring or the like; Qrepresents a single bond, aromatic ring, heterocyclic ring or the like; Qrepresents a groupor the like, Qrepresents an aromatic ring, heterocyclic ring or the like; and Trepresents &#x2014;CO&#x2014; or &#x2014;SO&#x2014;, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Sulfonyl derivatives

Growing community of inventors

Tokyo, Japan

Toshiharu Yoshino